Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients

Table 4 Univariate analysis for endoscopic recurrence n (%)

Endoscopic recurrence		Yes	No	P value
Gender	Female	3 (23.1)	10 (76.9)	0.775
	Male	3 (18.8)	13 (81.3)
Duration of the disease	≤ 10 yr	3 (23.1)	10 (76.9)	0.775
	> 10 yr	3 (18.8)	13 (81.3)
Pattern	Non-stricturing, non-penetrating	2 (22.2)	7 (77.8)	0.318
	Stricturing	4 (28.6)	10 (71.4)
	Penetrating	0 (0)	6 (100)
Extensive resection	Yes	5 (45.5)	6 (54.5)	0.026
	No	1 (5.6)	17 (94.4)
Immunomodulators concomitant to ADA	Yes	1 (20)	4 (80)	0.967
	No	5 (20.8)	19 (79.2)
Prior infliximab	Yes	5 (33.3)	10 (66.7)	0.111
	No	1 (7.1)	13 (92.9)
Previous resections	≤ 2	2 (9.1)	20 (90.9)	0.015
	> 2	4 (57.1)	3 (42.9)
Smoking status at diagnosis	Smokers	3 (21.4)	11 (78.6)	0.516
	Non-smokers	3 (23.1)	10 (76.9)
	Ex-smokers	0 (0)	2 (100)
Smoking status after the index operation	Smokers	2 (50)	2 (50)	0.119
	Non-smokers	4 (16)	21 (84)
Adverse events	Yes	0 (0)	1 (100)	0.454
	No	6 (22.2)	21 (77.8)

ADA: Adalimumab.